World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
79
Citations
21854
World Ranking
17606
National Ranking
8799

Kent A. Griffith publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Kent A. Griffith sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 363 publications — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Kent A. Griffith D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Kent A. Griffith sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 79 D-Index — 14th percentile

14% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Kent A. Griffith is affiliated with the University of Michigan-Ann Arbor in the United States. Their primary field of study is Medicine, with a strong concentration in Oncology and related subfields.

The scientist's research spans various areas including Oncology, Public Health, Environmental and Occupational Health, Gender Studies, Cancer Research, and Radiology, Nuclear Medicine, and Imaging.

Their research topics cover:

  • Diversity and Career in Medicine
  • Breast Cancer Treatment Studies
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Advances in Oncology and Radiotherapy
  • Health and Medical Research Impacts
  • Global Cancer Incidence and Screening
  • Multiple Myeloma Research and Treatments

Frequent coauthors collaborating with Kent A. Griffith include:

  • Reshma Jagsi
  • Lori J. Pierce
  • James A. Hayman
  • Frank A. Vicini
  • M.M. Dominello

Their work is often published in the following venues:

  • Journal of Clinical Oncology
  • International Journal of Radiation Oncology*Biology*Physics
  • JAMA Internal Medicine
  • JCO Oncology Practice
  • Journal of Women s Health

Representative papers authored or co-authored by Kent A. Griffith include:

  • Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer, 2020, JCI Insight
  • Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA, 2023, Journal of Clinical Oncology
  • Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma, 2020, Blood
  • Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial, 2023, The Lancet Oncology
  • A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01, 2022, Cancer

Best Publications

  • Siblings, day-care attendance, and the risk of asthma and wheezing during childhood.

    Thomas M. Ball;Jose A. Castro-Rodriguez;Kent A. Griffith;Catharine J. Holberg

  • Gender Differences in Time Spent on Parenting and Domestic Responsibilities by High-Achieving Young Physician-Researchers

    Shruti Jolly;Kent A. Griffith;Rochelle DeCastro;Abigail Stewart

  • The association of sleep-disordered breathing and sleep symptoms with quality of life in the Sleep Heart Health Study.

    C. M. Baldwin;K. A. Griffith;F. J. Nieto;G. T. O'Connor

  • Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.

    Ines A. Silva;Shoumei Bai;Karen McLean;Kun Yang

  • A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

    Andrzej J. Jakubowiak;Andrzej J. Jakubowiak;Dominik Dytfeld;Dominik Dytfeld;Kent A. Griffith;Daniel Lebovic

  • Sexual Harassment and Discrimination Experiences of Academic Medical Faculty.

    Reshma Jagsi;Kent A. Griffith;Rochelle Jones;Chithra R. Perumalswami

  • Gender differences in the salaries of physician researchers.

    Reshma Jagsi;Kent A. Griffith;Abigail Stewart;Dana Sambuco

  • Meta-Analysis of Survival in African American and White American Patients With Breast Cancer: Ethnicity Compared With Socioeconomic Status

    Lisa A. Newman;Kent A. Griffith;Ismail Jatoi;Michael S. Simon

  • Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis.

    Feng Ming Kong;Feng Ming Kong;James A. Hayman;Kent A. Griffith;Gregory P. Kalemkerian

  • Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996.

    Robin B. Harris;Kent Griffith;Thomas E. Moon

  • Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma

    Edward J. Kim;Vaibhav Sahai;Ethan V. Abel;Kent A. Griffith

  • Long-Term Financial Burden of Breast Cancer: Experiences of a Diverse Cohort of Survivors Identified Through Population-Based Registries

    Reshma Jagsi;John A.E. Pottow;Kent A. Griffith;Cathy Bradley

  • Ginger inhibits cell growth and modulates angiogenic factors in ovarian cancer cells

    Jennifer Rhode;Sarah K. Fogoros;Suzanna Maria Zick;Heather Wahl

  • Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation.

    Reshma Jagsi;Merav A. Ben-David;Jean M. Moran;Robin B. Marsh

  • Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors

    Anne F. Schott;Melissa D. Landis;Gabriela Dontu;Kent A. Griffith

  • Sex Differences in Attainment of Independent Funding by Career Development Awardees

    Reshma Jagsi;Amy R. Motomura;Kent A. Griffith;Soumya Rangarajan

  • Mentoring and the Career Satisfaction of Male and Female Academic Medical Faculty

    Rochelle DeCastro;Kent A. Griffith;Peter A. Ubel;Abigail Stewart

  • Full-Dose Gemcitabine and Concurrent Radiotherapy for Unresectable Pancreatic Cancer

    James D. Murphy;Saroja Adusumilli;Kent A. Griffith;Michael E. Ray

  • Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease

    Jennifer Williams;Peter C. Lucas;Kent A. Griffith;Milheon Choi

  • The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.

    Sandra C. Paek;Kent A. Griffith;Timothy M. Johnson;Vernon K. Sondak

Frequent Co-Authors

Reshma Jagsi
Reshma Jagsi University of Michigan–Ann Arbor
Lori J. Pierce
Lori J. Pierce University of Michigan–Ann Arbor
Steven J. Katz
Steven J. Katz University of Michigan–Ann Arbor
Theodore S. Lawrence
Theodore S. Lawrence University of Michigan–Ann Arbor
Dafydd G. Thomas
Dafydd G. Thomas University of Michigan–Ann Arbor
Alfred E. Chang
Alfred E. Chang University of Michigan–Ann Arbor
Peter A. Ubel
Peter A. Ubel Duke University
Ravi Vij
Ravi Vij Washington University in St. Louis
Abigail J. Stewart
Abigail J. Stewart University of Michigan–Ann Arbor
Monica Morrow
Monica Morrow Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in careers aligned with medicine but seeking flexible or alternative educational paths, online health degrees offer valuable opportunities. Today, aspiring nurses and healthcare professionals can start or advance their careers with degrees that suit different backgrounds and goals.

If you’re aiming for the highest level of academic achievement in nursing, consider exploring online nursing PhD programs, ideal for future nurse educators or researchers. Working RNs looking to expand their skills can benefit from the cheapest RN to BSN bridge options, which are both affordable and convenient.

Individuals without a nursing background but interested in fast-tracking into advanced nursing roles should review online MSN programs for non nurses. Additionally, those seeking flexible entry-level options can look at online ADN programs for non nurses, which offer an accessible start in the field.

Each pathway has unique admission requirements, timelines, and career outcomes, making it essential to choose the program that fits your aspirations and current credentials.

Best Scientists Citing Kent A. Griffith

Trending Scientists

Recently Published Articles